Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

Stock Information for Ventyx Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.